 DELRAY BEACH, Fla., Jan. 08, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. AzurRx or the Company NASDAQ: AZRX, a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal GI diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. 